Bicara Therapeutics (BCAX) vs First Tracks Biotherapeutics (TRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
First Tracks Biotherapeutics is the larger company by market cap ($1.09 billion vs $1.09 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCAX | TRAX |
|---|---|---|
| Share price | $16.42 | $30.59 |
| Market cap | $1.09B | $1.09B |
| 1-day change | -0.85% | -2.55% |
| YTD return | -2.44% | — |
| 1-year return | -9.63% | — |
| EPS (TTM) | $-3.08 | $-4.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $30.99 | $49.91 |
| 52-week low | $13.70 | $14.72 |
| Distance from 52-week high | -47.02% | -38.71% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +116.20% | +128.83% |
| Average volume | 605.61K | 792.69K |
| Shares outstanding | 66.17M | 35.73M |
| Employees | 103 | 104 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bicara Therapeutics
BCAX stock →Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About First Tracks Biotherapeutics
TRAX stock →First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 104 employees
BCAX vs TRAX FAQ
Which is bigger, Bicara Therapeutics or First Tracks Biotherapeutics?
First Tracks Biotherapeutics (TRAX) is larger, with a market capitalization of $1.09B compared with $1.09B for Bicara Therapeutics (BCAX).
Are Bicara Therapeutics and First Tracks Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.